Research Studio: compare compounds by goal and evidence

Start here

• Compound library
• Stack Builder
• Watch the 27-second tour
• Guided calculators

Evidence board entries

• Tirzepatide — FDA-approved products with current US labels (Zepbound, Mounjaro), supported by published randomised Phase 3 trials. The app catalog assigns no separate grade, so none is shown.
• Survodutide — Investigational. Phase 3 results so far come from a journal publication (SYNCHRONIZE-1) and a sponsor announcement (SYNCHRONIZE-CVOT). There is no approved label. The app catalog assigns no separate grade, so none is shown.
• SANA — Investigational oral small molecule (MVD1, a nitroalkene salicylate), not a peptide. One first-in-human Phase 1 study plus preclinical work. No approved product.
• MK-677 — Oral growth-hormone secretagogue receptor (GHSR) agonist, a small molecule. Not a peptide and not a SARM. No approved product; a pediatric Phase 3 (as LUM-201) is recruiting.
• FLGR-242 — Seller-described product only: follistatin linked to an albumin binder. Exact-name PubMed and ClinicalTrials.gov searches returned no records.
• Klotho — Several different things share the name: membrane klotho (an FGF23 co-receptor), soluble klotho, LR variants, and plasmid or mRNA constructs in early trials. No approved product.

Evidence and community reports are kept apart

The board columns show regulator decisions and published research only. Anecdotes, forum threads and community reports are kept on each compound page, labelled separately: they can raise questions, but uncontrolled reports cannot establish an effect.

Supplement context

Cited nutrition and lab topics worth discussing with a clinician. Not needed for everyone, and no amounts.

Optional: read the evidence like a reviewer

Four questions on reading research. No score, no points, nothing to take.